Figure 6.

Effect of napabucasin (BBI 608) alone or in combination with chemoradiotherapy on tumor growth, body weight, and steaminess of HCT 116 xenografts. (A). Significant differences in tumor volumes (p<0.0001) was observed in treated (napabucasin or IR or IR+FU or napabucasin and IR+FU) as compared to the untreated HCT 116 xenograft models. (B). HCT 116 xenograft models show no loss of body weight among the treatment groups. (C). Combined therapy with napabucasin and FU+IR led to significant inhibition of blood vessel formation as compared to chemoradiotherapy or napabucasin alone or control. Results are showed as mean ± SD (***p<0.0001). (D). Mechanism of BBI 608 action on DNA damage in CRC.